WO2003105850A1 - 2-aminoquinolines servant d'antagonistes de recepteur de l'hormone de concentration de melanine - Google Patents

2-aminoquinolines servant d'antagonistes de recepteur de l'hormone de concentration de melanine Download PDF

Info

Publication number
WO2003105850A1
WO2003105850A1 PCT/US2003/018959 US0318959W WO03105850A1 WO 2003105850 A1 WO2003105850 A1 WO 2003105850A1 US 0318959 W US0318959 W US 0318959W WO 03105850 A1 WO03105850 A1 WO 03105850A1
Authority
WO
WIPO (PCT)
Prior art keywords
amine
quinolin
oxy
methylbutoxy
methyl
Prior art date
Application number
PCT/US2003/018959
Other languages
English (en)
Inventor
Christine A. Collins
Ju Gao
Philip R. Kym
Jared C. Lewis
Andrew J. Souers
Anil Vasudevan
Dariusz Wodka
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/460,139 external-priority patent/US6989392B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO2003105850A1 publication Critical patent/WO2003105850A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to the antagonism of the effects of melanin- concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
  • MCH melanin- concentrating hormone
  • Obesity is a major cause and contributor to health problems such as type II diabetes, coronary heart disease, increased incidence of certain forms of cancer, and respiratory complications. It is a disease that is increasing at an alarming rate due to increased availability of high-fat diets, genetic susceptibility, and a more sedentary way of life in modern society. Obesity can be defined as weight gain resulting from a mismatch of energy intake and energy expenditure. Food intake and energy metabolism are regulated, in part, by the interaction of neuropeptides and their receptors. Recently, the role that the hormone leptin plays in controlling appetite has been elucidated. Leptin is a peptide hormone produced by fat cells, regulating both food intake and and metabolism by acting on leptin receptors in the hypothalamus.
  • MCH Melanin-concentrating hormone
  • MCH is a cyclic 19 amino acid neuropeptide expressed in the zona incerta and lateral hypothalamus in response to both energy restriction and leptin deficiency.
  • MCH is known to stimulate feeding when injected into the lateral ventricle of rats and the mRNA for MCH is upregulated in the hypothalamus of genetically obese mice (ob/ob) and in fasted control and ob/ob animals.
  • Mice lacking MCH are hypophagic and lean with increased metabolic rate, whereas animals over-expressing MCH gain excess weight on both standard and high fat diets.
  • GPCR G-protein coupled receptor
  • Li is a bond or is a member selected from the group consisting of-C(O)-, -0-, -S-, -S(O)-, and -S(O) 2 -;
  • Ri is a member selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, arylalkyl, arylalkoxy, arylcarbonyl, heterocycle, heterocyclealkyl, R A R B -, and R R ⁇ Ncarbonyl;
  • R 2 is a member selected from the group consisting of alkyl, alkoxy, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkoxyalkyl, R 7 L 2 R 6 -, RAS
  • a method of treating disorders mediated by MCH through the MCH receptor comprising administering a therapeutically effective amount of a compound of formula (I).
  • a method for treating eating disorders, weight gain and obesity comprising administering a therapeutically effective amount of a compound of formula (I).
  • a method for treating treating abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders comprising administering a therapeutically effective amount of a compound of formula (I).
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) in combination with a pharmaceutically suitable carrier.
  • alkenyl refers to a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens.
  • Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2 -propenyl, 3-butenyl, 4-pentenyl, 5- hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
  • alkoxy refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2- ⁇ ropoxy, butoxy, tert- butoxy, pentyloxy, and hexyloxy.
  • alkoxyalkyl refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2- ethoxy ethyl, 2-methoxy ethyl, and methoxymethyl.
  • alkoxycarbonyl refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
  • alkoxycarbonylalkyl refers to an alkoxycarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxycarbonylalkyl include, but are not limited to, 3 -methoxy carbonylpropyl, 4-ethoxycarbonylbutyl, and 2-tert-butoxycarbonylethyl.
  • alkyl refers to a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms.
  • alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n- pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3- dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
  • alkylcarbonyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1- oxopropyl, 2,2-dimethyl-l-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
  • alkylcarbonylalkyl refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • alkylcarbonylalkyl include, but are not limited to, 2- oxopropyl, 3,3 ⁇ dimethyl-2-oxopropyl, 3-oxobutyl, and 3-oxopentyl.
  • alkylcarbonyloxy refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy.
  • alkylsulfonyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
  • alkylthio refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
  • Representative examples of alkylthio include, but are not limited, methylsulfanyl, ethylsulfanyl, tert-butylsulfanyl, and hexylsulfanyl.
  • alkynyl refers to a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
  • Representative examples of alkynyl include, but are not limited, to acetylenyl, 1- propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
  • aryl refers to a monocyclic-ring system, or a bicyclic- or a tricyclic- fused ring system wherein one or more of the fused rings are aromatic.
  • Representative examples of aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.
  • aryl groups of this invention can be substituted with 1, 2, or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl.
  • Re and R D are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl.
  • arylalkoxy refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 3- naphth-2-ylpropoxy, and 5-phenylpentyloxy.
  • arylalkyl refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.
  • arylcarbonyl refers to an aryl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of arylcarbonyl include, but are not limited to, benzoyl and naphthoyl.
  • carbonyl refers to a -C(O)- group.
  • carboxyalkyl refers to a carboxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of carboxyalkyl include, but are not limited to, carboxymethyl, 2- carboxy ethyl, and 3-carboxypropyl.
  • cyano refers to a -CN group.
  • cyanoalkyl refers to a cyano group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of cyanoalkyl include, but are not limited to, cyanomethyl, 2- cyanoethyl, and 3-cyanopropyl.
  • cycloalkyl refers to a monocyclic, bicyclic, or tricyclic ring system.
  • Monocyclic ring systems are exemplified by a saturated cyclic hydrocarbon group containing from 3 to 8 carbon atoms. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Bicyclic ring systems are exemplified by a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms.
  • bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane.
  • Tricyclic ring systems are exemplified by a bicyclic ring system in which two non-adjacent carbon atoms of the bicyclic ring are linked by a bond or an alkylene bridge of between one and three carbon atoms.
  • tricyclic-ring systems include, but are not limited to, tricyclo[3.3.1.0 3 ' 7 ]nonane and tricyclo[3.3.1.1 3,7 ]decane (adamantane).
  • haloalkyl refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2- fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.
  • heterocycle or “heterocyclic,” as used herein, refers to a monocyclic, bicyclic, or tricyclic ring system.
  • Monocyclic ring systems are exemplified by any 3- or 4- membered ring containing a heteroatom independently selected from oxygen, nitrogen and sulfur; or a 5-, 6- or 7-membered ring containing one, two or three heteroatoms wherein the heteroatoms are independently selected from nitrogen, oxygen and sulfur.
  • the 5-membered ring has from 0-2 double bonds and the 6- and 7-membered ring have from 0-3 double bonds.
  • monocyclic ring systems include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepinyl, 1,3-dioxolanyl, dioxanyl, dithianyl, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, isothiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridinyl,
  • Bicyclic ring systems are exemplified by any of the above monocyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or another monocyclic ring system.
  • Representative examples of bicyclic ring systems include but are not limited to, for example, benzimidazolyl, benzodioxinyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, benzofiiranyl, benzopyranyl, benzothiopyranyl, cinnolinyl, indazolyl, indolyl, 2,3-dihydroindolyl, indolizinyl, naphthyridinyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, phthalazinyl, 4H-pyrido[l,2- ⁇ ]pyrimidin-4
  • Tricyclic rings systems are exemplified by any of the above bicyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or a monocyclic ring system.
  • Representative examples of tricyclic ring systems include, but are not limited to, acridinyl, carbazolyl, carbolinyl, dibenzo[b,d]furanyl, dibenzo[b,d]thienyl, naphtho[2,3- bjfuran, naphtho[2,3-b]thienyl, phenazinyl, phenothiazinyl, phenoxazinyl, thianthrenyl, thioxanthenyl and xanthenyl.
  • heterocycles of this invention can be substituted with 1, 2,or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkyl, arylcarbonyl, aryloxy, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, halogen, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, phenyl, and RcR ⁇ N-, RcR ⁇ Ncarbonyl, RcR ⁇ Nalkyl, wherein Re and R ⁇ are defined herein.
  • heterocyclealkyl refers to a heterocycle, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heterocyclealkyl include, but are not limited to, pyridin-3- ylmethyl and 2-pyrimidin-2-ylpropyl and the like.
  • hydroxy refers to an -O ⁇ group.
  • hydroxyalkyl refers to a hydroxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, 2-hydroxyethyl, 2- hydroxypropyl, 3-hydroxybutyl and the like.
  • mercapto refers to a -SH group.
  • RAR B N- refers to both R A and R B appended to the parent molecular moiety through a -N- group.
  • nitro refers to a -NO 2 group.
  • RAR B Nalkyl refers to a R A R B N group, as defined herein, appended to the parent molecular ' moiety through an alkyl group, as defined herein.
  • R A R- B Ncarbonyl refers to a A R B N group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • R A S refers to a A group, as defined herein, appended to the parent molecular moiety through a -S- group, as defined herein.
  • R A Salkyl refers to a R A S group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • the present invention is directed to compounds of formula (I), wherein Rj, R , R 3 ,
  • R4, R 5 , R , R B , and L are defined herein.
  • the compounds of thepresent invention are useful for treating disorders mediated by MCH through the MCH receptor.
  • a method of treating or preventing disorders mediated by MCH through the MCH receptor comprising administrering a therapeutically effective amount of a compound of formula (I).
  • Li is a bond or is a member selected from the group consisting of -C(O)-, -0-, -S-, -S(O)-, and -S(0) -;
  • R ⁇ is a member selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, arylalkyl, arylalkoxy, arylcarbonyl, heterocycle, heterocyclealkyl, R R B N-, and R RsNcarbonyl;
  • R 2 is a member selected from the group consisting of alkyl, alkoxy, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkoxyalkyl, R 7 L 2 R 6 - whom R A Salkyl
  • R is a member selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, arylalkyl, arylalkoxy, arylcarbonyl, heterocycle, heterocyclealkyl, R A R B N-, and RAR B Ncarbonyl;
  • R 2 is a member selected from the group consisting of alkyl, alkenyl;
  • R 3 is a member selected from the group consisting of hydrogen, alkyl, hydroxy, cyano, halo, haloalkoxy, R A R B N-, and alkylcarbonylNH-;
  • R ⁇ and R 5 are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, cyano, halo, haloalkoxy, R A R ⁇ N-, and alkylcarbonylNH-;
  • R A and R B are each independently a member selected from the group consisting of hydrogen,
  • a compound according to formula (la), or a therapeutically suitable salt or prodrug thereof wherein Li is-O-; Ri is a member selected from the group consisting of alkyl, alkoxy, aryl, arylalkyl, arylalkoxy, arylcarbonyl, heterocycle, heterocyclealkyl, R A R B N- and R R B carbonyl; R 2 is a member selected from the group consisting of alkyl, alkenyl; R 3 is a member selected from the group consisting of hydrogen, alkyl, hydroxy, cyano, halo, haloalkoxy, R A R B N-, and alkylcarbonylNH-; R4, and R 5 are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, cyano, halo, haloalkoxy, R A R B N-, and alkylcarbonylNH-; R A and R B are each
  • Rt is a member selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, arylalkyl, arylalkoxy, arylcarbonyl, heterocycle, heterocyclealkyl, R A R B N-, and R A R B Ncarbonyl
  • R 2 is alkyl, wherein alkyl is C 6 or larger
  • R 3 is a member selected from the group consisting of hydrogen, alkyl, hydroxy, cyano, halo, haloalkoxy, R A R B N-, and alkylcarbonylNH-
  • R ⁇ and R 5 are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, cyano, halo, haloalkoxy, R A R B -, and alkylcarbonylNH-
  • RA and R B are each independently a member selected from the group consisting of hydrogen
  • Rt is a member selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, arylalkyl, arylalkoxy, arylcarbonyl, heterocycle, heterocyclealkyl, R R B N-, and R A R B Ncarbonyl
  • R 2 is a member selected from the group consisting of alkoxyalkyl, haloalkyl, R Salkyl, and R A R ⁇ Nalkyl
  • R 3 is a member selected from the group consisting of hydrogen, alkyl, hydroxy, cyano, halo, haloalkoxy, R A R B N-, and alkylcarbonylNH-
  • R t , and R 5 are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, cyano, halo, haloalkoxy, R A R B N-, and alkylcarbonylNH-
  • R t , and R 5 are each independently a member selected
  • Ri is a member selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, arylalkyl, arylalkoxy, arylcarbonyl, heterocycle, heterocyclealkyl, R A R B N-, and R A R ⁇ Ncarbonyl
  • R 2 is a member selected from the group consisting of aryl, cycloalkyl and heterocycle
  • R 3 is a member selected from the group consisting of hydrogen, alkyl, hydroxy, cyano, halo, haloalkoxy, RAR B N-, and alkylcarbonylNH-
  • R_ t , and R 5 are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, cyano, halo, haloalkoxy, R A R B N-, and alkylcarbonylNH-
  • R A and R B are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy
  • R t is a member selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, arylalkyl, arylalkoxy, arylcarbonyl, heterocycle, heterocyclealkyl, R A R B N-, and R A B Ncarbonyl;
  • R is a member selected from the group consisting of arylalkyl, aryloxyalkyl, cycloalkylalkyl, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxyalkoxyalkyl, R 7 L 2 R 6 -;
  • R 3 is a member selected from the group consisting of hydrogen, alkyl, hydroxy, cyano, halo, haloalkoxy,
  • R 4 , and R 5 are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxy, cyano, halo, haloalkoxy, R A R B -, and alkylcarbonylNH-;
  • R A and B are each independently a member selected from the group consisting of hydrogen, alkyl, aryl and heterocycle.
  • a method for treating eating disorders, weight gain and obesity comprising administering a therapeutically effective amount of a compound of formula (I).
  • a method for treating abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders comprising administering a therapeutically effective amount of a compound of formula (I).
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) in combination with a pharmaceutically suitable carrier.
  • Specific compounds of formula (I) include, but are not limited to:
  • the present compounds can exist as therapeutically suitable salts.
  • therapeutically suitable salt refers to salts or zwitterions of the compounds which are water or oil-soluble or dispersible, suitable for treatment of disorders without undue toxicity, irritation, and allergic response, commensurate with a reasonable benefit/risk ratio, and effective for their intended use.
  • the salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group of the compounds with a suitable acid.
  • Representative salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, isethionate, fumarate, lactate, maleate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, oxalate, maleate, pivalate, propionate, succinate, tartrate, trichloroacetic, trifluoroacetic, glutamate, para-toluenesulfonate, undecanoate, hydrochloric, hydrobromic, sulfuric, phosphoric, and the like.
  • the amino groups of the compounds can also be quaternized with alkyl chlorides, bromides, and iodides such as methyl, ethyl, propyl, isopropyl, butyl, lauryl, myristyl, stearyl, and the like.
  • the present invention contemplates pharmaceutically suitable salts formed at the nitrogen attached to 2-amino group of formula (I), when R t is selected from hydrogen, alkyl, alkoxy, aryl, arylalkyl, heterocycle, heterocyclealkyl, R A R ⁇ N.
  • Basic addition salts can be prepared during the final isolation and purification of the present compounds by reaction of a carboxyl group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation such as lithium, sodium, potassium, calcium, magnesium, or aluminum, or an organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation such as lithium, sodium, potassium, calcium, magnesium, or aluminum, or an organic primary, secondary, or tertiary amine.
  • the present compounds can also exist as therapeutically suitable prodrugs.
  • therapeutically suitable prodrug refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
  • prodrug refers to compounds which are rapidly transformed in vivo to the parent compounds of formula (I) for example, by hydrolysis in blood.
  • Asymmetric centers can exist in the present compounds. Individual stereoisomers of the compounds are prepared by synthesis from chiral starting materials or by preparation of racemic mixtures and separation by conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of the enantiomers on chiral chromatographic columns. Starting materials of particular stereochemistry are either commercially available or are made by the methods described hereinbelow and resolved by techniques well-known in the art. Geometric isomers can exist in the present compounds The invention contemplates the various geometric isomers and mixtures thereof resulting from the disposal of substituents around a carbon-carbon double bond, a cycloalkyl group, or a heterocycloalkyl group. Substituents around a carbon-carbon double bond are designated as being of Z or E configuration and substituents around a cycloalkyl or heterocycloalkyl are designated as being of cis or trans configuration.
  • compositions of the present compounds comprise an effective amount of the same formulated with one or more therapeutically suitable excipients.
  • therapeutically suitable excipient represents a non-toxic, solid, semi-solid or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type.
  • therapeutically suitable excipients include sugars; cellulose and derivatives thereof; oils; glycols; solutions; buffering, coloring, releasing, coating, sweetening, flavoring, and perfuming agents; and the like.
  • These therapeutic compositions can be administered parenterally, intracisternally, orally, rectally, or intraperitoneally.
  • Liquid dosage forms for oral administration of the present compounds comprise formulations of the same as emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms can contain diluents and/or solubilizing or emulsifying agents.
  • the oral compositions can include wetting, emulsifying, sweetening, flavoring, and perfuming agents.
  • injectable preparations of the present compounds comprise sterile, injectable, aqueous and oleaginous solutions, suspensions or emulsions, any of which can be optionally formulated with parenterally suitable diluents, dispersing, wetting, or suspending agents.
  • injectable preparations can be sterilized by filtration through a bacterial-retaining filter or formulated with sterilizing agents which dissolve or disperse in the injectable media.
  • Antagonism of the effects of MCH through the MCH receptor by the compounds of the present invention can be delayed by using a liquid suspension of crystalline or amorphous material with poor water solubility.
  • the rate of absorption of the compounds depends upon their rate of dissolution which, in turn, depends on their crystallinity. Delayed absorption of a parenterally administered compound can be accomplished by dissolving or suspending the compound in oil.
  • injectable depot forms of the compounds can also be prepared by microencapsulating the same in biodegradable polymers.
  • Solid dosage forms for oral administration of the present compounds include capsules, tablets, pills, powders, and granules.
  • the compound is mixed with at least one inert, therapeutically suitable excipient such as a carrier, filler, extender, disintegrating agent, solution retarding agent, wetting agent, absorbent, or lubricant.
  • the excipient can also contain buffering agents.
  • Suppositories for rectal administration can be prepared by mixing the compounds with a suitable non-irritating excipient which is solid at ordinary temperature but fluid in the rectum.
  • the present compounds can be micro-encapsulated with one or more of the excipients discussed previously.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric and release-controlling.
  • the compounds can be mixed with at least one inert diluent and can optionally comprise tableting lubricants and aids.
  • Capsules can also optionally contain opacifying agents which delay release of the compounds in a desired part of the intestinal tract.
  • Transdermal patches have the added advantage of providing controlled delivery of the present compounds to the body.
  • dosage forms are prepared by dissolving or dispensing the compounds in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compounds across the skin, and the rate of absorption can be controlled by providing a rate controlling membrane or by dispersing the compounds in a polymer matrix or gel.
  • Disorders caused or exacerbated by MCH are treated or prevented in a patient by administering to the patient, a therapeutically effective amount of compound of the present invention in such an amount and for such time as is necessary to achieve the desired result.
  • terapéuticaally effective amount refers to a sufficient amount of a compound to effectively emeliorate disorders mediated by MCH, by antagonizing the effect of MCH through the MCH receptor at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the compound employed; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, rate of excretion; the duration of the treatment; and drugs used in combination or coincidental therapy.
  • the total daily dose of the present compounds in single or divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight.
  • treatment regimens comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compounds per day in single or multiple doses.
  • MCHR melanin concentrating hormone receptor
  • the assays are performed as follows. HEK293 cells expressing the murine MCHR are plated overnight at 50,000 cells/well in 96-well plates. The following day, culture medium is removed and replaced with 100 ⁇ l/well of D-PBS (+glucose and sodium pyruvate) containing 2.5 ⁇ M Fluo-4AM (Molecular Probes), 0.01% Pluronic F-127 and 2.5 mM probenecid. Cells are loaded with the Fluo-4 dye for at least one hour at room temp. After loading, the cells are washed gently to remove extracellular dye and 100 ⁇ l of D-PBS (+glucose and sodium pyruvate) is added to each well. Test compounds are prepared at 40 ⁇ M in 4% DMSO.
  • the cell plate is placed in the FLIPRTM and 50 ⁇ l/well of test compound is delivered.
  • the calcium signal is followed for 3 minutes to assay for potential agonist activity by the test compounds.
  • 50 ⁇ l/well of 12 nM human MCH in D-PBS containing 0.1% BSA
  • the ligand-induced calcium signal is followed for an additional 3 minutes.
  • fTC MCH-induced fluorescence in the presence of test compound
  • fMCH MCH-induced fluorescence in the absence of test compound
  • fB Baseline fluorescence.
  • the compounds of the present invention inhibit MCH induced fluorescence at a dose of 10 ⁇ M.
  • compounds of the present invention inhibit MCH induced fluorescence in a range of about 75 to about 100% inhibition of MCH at a dose of 10 ⁇ M. More preferably compounds of the present invention inhibit MCH induced fluorescence in a range of about 90 to about 100% inhibition of MCH at a dose of 10 ⁇ M.
  • the compounds of the present invention are useful in treating disorders that are mediated by MCH through the MCH receptor, such as obesity.
  • m-CPBA meta-chloroperoxy-benzoic acid
  • DMF for N,N- dimethylformamide
  • DMSO for dimethylsulfoxide
  • ED AC for l-(3-dimethylaminopropyl)- 3-ethylcarbodiimide hydrochloride
  • HOBT for 1 -hydroxybenzotriazole hydrate
  • NMP for N- methylpyrrolidinone
  • THF for tetrahydrofuran
  • TFA trifluoroacetic acid
  • Pd(dppf)Cl 2 for (diphenylphospino)ferrocenyl palladium chloride.
  • compounds of formula 1 can be reacted with m-CPBA followed by a reaction with phosphorous oxychloride to provide compounds of formula 2.
  • the reaction of compound of formula 1 with m-CPBA are generally carried out in solvents such as but not limited to chloroform, dichloromethane, benzene and the like and are generally done at 25 °C for 20 minutes.
  • the further reaction with phosphorous oxychloride are generally carried out in solvents such as but not limited to chloroform, dichloromethane, benzene and the like and are generally done at 100 °C for 15 minutes.
  • Compounds of formula 2 can then be reacted with amines of formula 3 in the presence of a base to provide compounds of formula 4.
  • Typical bases used in the reaction include but are not limited to triethylamine, diisopropylethylamine and typical solvents include but not limited to tetrahydrofuran, acetonitrile and the like.
  • bases such as sodium hydride in solvents such as but not limited to DMF may be utilized in the transformation.
  • compounds of general formula 5 can be reacted with aldehydes of general formula 6 in the presence of a reducing agent such as but not limited to sodium cyanoborohydride, sodium borohydride and sodium triacetoxyborohydride in solvents such as but not limited to THF and the like to provide compounds of formula 4.
  • a reducing agent such as but not limited to sodium cyanoborohydride, sodium borohydride and sodium triacetoxyborohydride in solvents such as but not limited to THF and the like to provide compounds of formula 4.
  • Reactions are performed at temperatures ranging from 25 to 80 °C and are generally complete between 5 and 96 hours.
  • compounds of general formula 5 can be reacted with compounds of formula 7 (wherein X is halogen) in the presence of a base to provide compounds of formula 4.
  • the reactions are typically carried out at 60 °C in solvents including but not limited to acetonitrile, DMF, THF and the like, and reactions are generally complete within 6-18 hours.
  • compounds of formula 5 wherein L is selected from the group consisting of-O-, -S-, or a covalent bond
  • compounds of formula 8 wherein Ri is alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl in the presence of a base to provide compounds of formula 9.
  • Typical bases include but are not limited to triethylamine, diisopropylethylamine and the like. Reactions are typically carried out at 25 °C for 1-10 hours.
  • Compounds of formula 9 can be reacted with an excess of butyl lithium at -78 °C for 4 hours in solvents including but not limited to THF followed by the reaction with compounds of formula K), wherein R 3 is alkyl, to provide compounds of formula 11.
  • Compounds of formula 11 can be reacted with reagents commonly known to those skilled in the art which are useful for the hydrolysis of amides to provide compounds of formula 12.
  • Such reagents and conditions useful for the hydrolysis of amides include but are not limited to sodium or potassium hydroxide in aqueous solvent mixtures such as but not limited to aqueous isopropanol and aqueous tetrahydrofuran and the like. Reactions may or may not need to be heated to 50-70 °C for 1-10 hours.
  • compounds of formula 13 can be reacted with compounds of formula 14 in the presence of a base such as but not limited to triethylamine, diisopropylethylamine and the like to provide compounds of formula L5.
  • a base such as but not limited to triethylamine, diisopropylethylamine and the like.
  • Typical reaction conditions may involve heating to 50 °C in such solvents that include but are not limited to acetonitrile, THF and DMF.
  • sodium hydride in DMF may be utilized for this transformation.
  • compounds of formula 13 can be reacted with compounds of formula 8 in the presence of triphenylphosphine and a dialkyl azodicarboxylate such as but not limited to dimethyl azodicarboxylate, diethyl azodicarboxylate, diisopropyl azodicarboxylate and dicyclohexyl azodicarboxylate at 0 °C in solvents such as but not limited to THF, diethyl ether and the like to provide compounds of formula 20.
  • triphenylphosphine and a dialkyl azodicarboxylate such as but not limited to dimethyl azodicarboxylate, diethyl azodicarboxylate, diisopropyl azodicarboxylate and dicyclohexyl azodicarboxylate at 0 °C in solvents such as but not limited to THF, diethyl ether and the like to provide compounds of formula 20.
  • compounds of formula 13 can be reacted with trifluoromethanesulfonic anhydride and a base to provide compounds of formula 24.
  • Typical reactions utilize bases such as but not limited to triethylamine, diisopropylethylamine and the like and are carried out in solvents including but not limited to THF and dichloromethane and are generally done at 0 °C.
  • organozinc reagents represented by the formula R 2 ZnX (wherein R 2 is alkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, and X represents a halogen) in the presence of Pd(dppf)Cl 2 to provide compounds of formula 25.
  • organozinc reagents represented by the formula R 2 ZnX (wherein R 2 is alkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycleoxyalkyl, and X represents a halogen) in the presence of Pd(dppf)Cl 2 to provide compounds of formula 25.
  • compounds of formula 24 can be reacted with carbon dioxide in the presence of Pd(dppf)Cl 2 and a base in methanol to provide compounds of formula 26.
  • Compounds of formula 26 can be reacted with compounds of formula R'M (wherein R' is alkyl, alkoxy, aryl, cycloalkyl; and M is lithium or magnesium bromide) to provide compounds of formula 27.
  • Compounds of formula 27 can be reacted with compounds of formula R 2 X, (wherein R 2 is previously described in formula (I), but is not hydrogen; and X is halogen) and a base to provide compounds of formula 28.
  • Typical bases utilized in the transformation of compounds of formula 27 to compounds of formula 28 include but are not limited to sodium hydride in DMF and potassium hydroxide in dimethyl sulfoxide.
  • compounds of formula 30 can be reacted with methanesulfonyl chloride in the presence of a base such as but not limited to triethylamine, diisopropylethylamine, N-methylmorpholine and the like in solvents such as but not limited to dichloromethane and THF to provide compounds of general formula 30 A.
  • a base such as but not limited to triethylamine, diisopropylethylamine, N-methylmorpholine and the like in solvents such as but not limited to dichloromethane and THF
  • compounds of general formula 30 A can be reacted with alcohols of formula 18 in the presence of a base such as but not limited to triethylamine, diisopropylethylamine and the like in solvents such as but not limited to THF, acetonitrile and the like to provide compounds of general formula 3L
  • compounds of formula 26 can also be converted to compounds of formula 32 through hydrolysis of the ester functionality to provide the carboxylic acid which can be converted to the amide 32 through methods commonly known to those skilled in the art.
  • the conversion of the amide 32 to compounds of formula 33 by the addition of organometallic reagents wherein R 2 is alkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, and M is magnesium bromide is well known to those skilled in the art.
  • compounds of formula 1 _ can be reacted with sodium hydride in solvents such as but not limited to THF and DMF followed be a reaction with dimethylthiocarbamoyl chloride to provide compounds of formula 34.
  • Compounds of formula 32 can then be heated to provide compounds of formula 35.
  • Compounds of formula 35 can be reacted with potassium hydroxide to hydrolyze the carbamoyl functionality followed by a reaction with R 2 X with a base to provide compounds of formula 36.
  • Compounds of formula 36 can be reacted with meta-chloroperoxybenzoic acid to provide either the compounds of formula 37, wherein n is either 1 or 2.
  • the product of the oxidation with m-CPBA to provide sulfone or the sulfoxide has been established in the literature and is known to those skilled in the art.
  • compounds of general formula 13 can be reacted with heterocycles of general formula 38 using the same conditions described in Scheme 7 to provide compounds of general formula 39, wherein P is a nitrogen protecting group such as but not limited to acetyl, benzyl, tert-butoxycarbamate, benzylcarbamate and allylcarbamate.
  • P is a nitrogen protecting group such as but not limited to acetyl, benzyl, tert-butoxycarbamate, benzylcarbamate and allylcarbamate.
  • Compounds of general formula 39 can be reacted under conditions known to those skilled in the art to remove nitrogen protecting groups to provide compounds of general formula 40.
  • the nitrogen protecting groups used in the compounds described within are specific to the protecting group used for each example and can be found in the description in Greenes "Protecting groups in Organic Chemistry" 3 rd ed. 1999, Wiley & Sons, Inc.
  • a typical protecting group used in these examples described within is tert-butoxycarbonyl which can be removed by the reaction with either 4N HCl in dioxane or trifluoroacetic acid in dichloromethane.
  • Compounds of general formula 40 can be reacted with compounds of general formula 41, wherein R 7 , L 2 are defined in formula (I), r is 1, 2, or 3 and X is halogen with a base such as but not limited to triethylamine, diisopropylethylamine and the like in solvents such as but not limited to THF, acetonitrile and the like to provide compounds of general formula 42.
  • compounds of general formula 13 can be reacted with compounds of general formula 43 wherein LG is a leaving group such as but not limited to mesyl, triflic, or halogen, in the presence of a base such as but not limited to triethylamine, diisopropylethylamine and the like under heating conditions to provide compounds of general formula 39.
  • Typical conditions for this reaction include heating the reaction mixture to 65 °C in solvents such as but not limited to THF or acetonitrile for 12 to 24 hours.
  • Compounds of general formula 39 can then be reacted under conditions described in Scheme 15 to provide compounds of general formula 42.
  • Example 1 8-isopropox ⁇ quinolin-2-amine
  • a reaction vessel of the PE Biosystems Solaris 530TM Organic Synthesizer was charged with PS-PPh resin (Aldrich Chemical Co., Inc, 176 mg, 4.2 equiv for reactions involving a secondary alcohol; 88 mg, 2.1 equiv for reactions involving a primary alcohol), and purged by passing a stream of N 2 for 45 seconds.
  • THF was added to the vessel and the resultant suspension was shaken for 15 min. Then, a solution of DBAD (0.50 mL; 46 mg/mL; 1.6 equiv) in anhydr.
  • Example 2 8-(cyclobutyloxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting cyclobutanol for isopropylalcohol.
  • J H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.94 (d, IH), 7.94 (d, IH), 7.27 (m, IH), 7.19 (m, IH), 7.08 (m, IH), 4.82 (m, IH), 2.48 (m, 4H), 1.95 (m, IH), 1.73 (m, IH); MS (DCI/NH 3 ) m z 215 [M+H] + .
  • Example 4 8-(cyclopentyloxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting cyclopentanol for isopropylalcohol.
  • X H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.96 (d, IH), 7.30 (m, IH), 7.19 (m, IH), 7.09 (m, IH), 7.04 (d, IH), 4.94 (m, IH), 2.13 (m, 2H), 1.97 (m, 4H), 1.64 (m, 2H); MS (DCI/NH 3 ) m z 229 [M+H] + .
  • Example 7 8-( 1 -ethy lpropoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 3-pentanol for isopropylalcohol. ! H NMR (500 MHz, CDC1 3 ) ⁇ ppm 7.95 (d, IH), 7.29 (t, IH), 7.19 (m, IH), 7.10 (m, 2H), 4.34 (m, IH), 1.93 (m, 2H), 1.79 (m, 2H), 0.99 (t, 6H); MS (DCI/NH 3 ) m z 231 [M+H] + .
  • Example 8 8-(2-methoxy-l-methylethoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting l-methoxy-2-propanol for isopropylalcohol.
  • H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.95 (d, IH), 7.30 (m, IH), 7.21 (m, 2H), 7.05 (d, IH), 4.76 (m, IH), 3.93 (dd, IH), 3.60 (dd, IH), 3.41 (s, 3H), 1.42 (d, 3H); MS (DCI/NH 3 ) m/z 233 [M+H] + .
  • Example 10 8-((3-methylcyclopentyl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 3-methylcyclopentanol for isopropylalcohol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.96 (d, IH), 7.28 (t, IH), 7.19 (m, IH), 7.05 (m, 2H), 4.97 (m, 0.6H), 4.90 (m, 0.4H), 2.40 (m, IH), 2.26 (m, 1.6H), 1.93-2.16 (m, 1.8H), 1.81 (m, 0.4H), 1.70 (m, 0.4H), 1.57 (m, 0.4H), 1.46 (m, 0.8H), 1.17 (m, 0.6H), 1.10 (d, 1.2H), 1.03 (d, 1.8H); MS (DCI/NH 3 ) m/z 243 [M+H] + .
  • Example 12 8-(2-ethoxy- 1 -methylethoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting l-ethoxy-2-propanol for isopropylalcohol.
  • Example 13 8-((3-methylcyclohexyl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 3-methylcyclohexanol for isopropylalcohol. Mixture of isomers.
  • Example 16 8-( 1 ,3 ,3 -trimethylbutoxy quinolin-2-amine The title compound was prepared according to the procedure described in Example 1 substituting 4,4-dimethyl-2-pentanol for isopropylalcohol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.95 (d, IH), 7.31 (t, IH), 7.19 (d, IH), 7.15 (d, IH), 7.09 (d, IH), 4.73 (m, IH), 2.30 (dd, IH), 1.49 (dd, IH), 1.39 (d, 3H), 0.96 (s, 9H); MS (DCI/NH 3 ) m z 259 [M+H] + .
  • Example 17 8-(2-ethyl- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 3-ethyl-2-pentanol for isopropylalcohol.
  • H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.95 (d, IH), 7.29 (t, IH), 7.18 (d, IH), 7.11 (d, IH), 7.09 (d, IH), 4.61 (m, IH), 1.82 (m, IH), 1.66 (m, IH), 1.54 (m, 2H), 1.39 (d, 3H), 1.32 (m, IH), 0.94 (t, 3H), 0.89 (t, 3H); MS (DCI/NH 3 ) m z 259 [M+H] + .
  • Example 19 8-propo ⁇ yquinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 1-propanol for isopropylalcohol.
  • 1H NMR 500 MHz, CDCI3 ⁇ ppm 7.96 (d, IH), 7.30 (t, IH), 7.21 (m, IH), 7.08 (m, 2H), 4.13 (t, 2H), 2.01 (m, 2H), 1.09 (t, 3H); MS (DCI ⁇ NH3) m z 203 [M+H] + .
  • Example 20 8-butoxyquinolin-2-amine The title compound was prepared according to the procedure described in Example 1 substituting 1-butanol for isopropylalcohol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.96 (d, IH), 7.30 (t, IH), 7.21 (d, IH), 7.09 (d, IH), 7.09 (d, IH), 4.17 (t, 2H), 1.97 (m, 2H), 1.53 (m, 2H), 0.99 (t, 3H); MS (DCI/NH3) m/z 217 [M+H] + .
  • Example 22 8-(cyclobutylmethoxy)quinolin-2 -amine
  • the title compound was prepared according to the procedure described in Example 1 substituting cyclobutylmethanol for isopropylalcohol.
  • H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.95 (d, IH), 7.30 (t, IH), 7.20 (m, IH), 7.07 (m, 2H), 4.16 (d, 2H), 3.05 (m, IH), 2.25 (m, 2H), 1.78-2.07 (m, 4H); MS (DCI NH3) m z 229 [M+H] + .
  • Example 24 8-(pentyloxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 1 substituting 1-pentanol for isopropylalcohol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.97 (d, IH), 7.30 (t, IH), 7.21 (d, IH), 7.10 (d, IH), 7.07 (d, IH), 4.16 (t, 2H), 2.00 (m, 2H), 1.43 (m, 4H), 0.93 (t, 3H); MS (DCI/NH 3 ) m/z 231 [M+H] + .
  • Example 25 8-(2-methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 2-methyl-l-butanol for isopropylalcohol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.96 (d, IH), 7.30 (t, IH), 7.21 (d, IH), 7.08 (m, 2H), 4.05 (m, IH), 3.91 (m, IH), 2.18 (m, IH), 1.61 (m, IH), 1.34 (m, IH), 1.09 (d, 3H), 0.97 (t, 3H); MS (DCI NH 3 ) m/z 231 [M+H] + .
  • Example 27 8-(2-(methylthio)ethoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 2-(methylthio)ethanol for isopropylalcohol.
  • H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.98 (d, IH), 7.32 (t, IH), 7.26 (m, IH), 7.14 (d, IH), 7.06 (d, IH), 4.34 (t, 2H), 3.13 (t, 2H), 2.22 (s, 3H); MS (DCI/NH 3 ) m/z 235 [M+H] + .
  • Example 28 8-(cyclopentylmethoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting cyclopentylmethanol for isopropylalcohol.
  • 2 H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.95 (d, IH), 7.29 (t, IH), 7.20 (d, IH), 7.10 (d, IH), 7.07 (d, IH), 4.04 (d, 2H), 2.65 (m, IH), 1.97 (m, 2H), 1.64 (m, 4H), 1.30 (m, 2H); MS (DCI NH 3 ) m/z 243 [M+H] + .
  • Example 29 8-(tetrahydrofuran-3-ylmethoxy)qu ⁇ nolm-2-amme
  • the title compound was prepared according to the procedure described in Example 1 substituting tetrahydro-3-furanmethanol for isopropylalcohol.
  • H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.99 (d, IH), 7.31 (t, IH), 7.25 (d, IH), 7.11 (d, IH), 7.05 (d, IH), 4.09 (m, 2H), 3.96 (m, 2H), 3.78 (m, 2H), 3.11 (m, IH), 2.28 (m, IH), 1.73 (m, IH); MS (DCI/NH 3 ) m/z 245
  • Example 31 8-(3,3-dimethylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 3,3-dimethylbutanol for isopropylalcohol.
  • H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.96 (d, IH), 7.30 (t, IH), 7.21 (m, IH), 7.10 (m, 2H), 4.23 (t, 2H), 1.99 (t, 2H), 1.01 (s, 9H); MS (DCI NH3) m z 245 [M+H] + .
  • Example 33 8-(cyclohexylmethoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting cyclohexylmethanol for isopropylalcohol.
  • Example 34 8-(3-methoxy-3-methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 3-methoxy-3-methyl-l-butanol for isopropylalcohol.
  • H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.98 (d, IH), 7.31 (t, IH), 7.22 (m, IH), 7.16 (m, IH), 7.05 (d, IH), 4.28 (t, 2H), 3.23 (s, 3H), 2.30 (t, 2H), 1.27 (s, 6H); MS (DCI NH 3 ) m z 261 [M+H] + .
  • Example 35 8-(2-cyclohexylethoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 1 substituting 2-cyclohexylethanol for isopropylalcohol.
  • 1H NMR 500 MHz, CDCI 3 ) ⁇ ppm 7.96 (d, IH), 7.29 (t, IH), 7.20 (d, IH), 7.09 (m, 2H), 4.21 (t, 2H), 1.94 (m, 2H), 1.78 (m, 2H), 1.71 (m, 2H), 1.65 (m, IH), 1.51 (m, IH), 1.12-1.34 (m, 3H), 1.02 (m, 2H); MS (DCI/NH 3 ) m/z 271 [M+H] + .
  • Example 36 8-((lS,4R)-bicyclo[2.2.11hept-2-ylmethoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 1 substituting 2-norbornanemethanol for isopropylalcohol.
  • Example 37 8-((l-ethylpentyl)oxy)quinolin-2-amine
  • a reaction vessel of the PE Biosystems Solaris 530TM Organic Synthesizer was charged with 230 mg PS-PPh 3 resin (Aldrich Chemical Co., Inc, 5.50 equiv), and purged by passing a stream of N 2 for 45 seconds.
  • THF was added to the vessel and the resultant suspension was shaken for 15 min.
  • a solution of DBAD (0.50 mL; 46 mg/mL; 1.6 equiv) in anhydr.
  • Example 38 8-(((l R)- 1 -methylpropyl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 37 substituting (2S)-butan-2-ol for heptan-3-ol.
  • l R NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.94 (d, IH), 7.29 (t, IH), 7.19 (m, IH), 7.10 (d, IH), 7.07 (d, IH), 4.38-4.58 (m, IH), 2.00 (m, IH), 1.73 (m, IH), 1.43 (d, 3H), 1.01 (t, 3H); MS (DCI/NH 3 ) m/z 217 [M+H] + .
  • Example 40 8-(l-ethyl-2-methylpropoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 41 8-((( 1 R,2S)-2-methylcyclohexyl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 37 substituting trans-2-methylcyclohexanol for heptan-3-ol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.93 (d, IH), 7.28 (t, IH), 7.13 (m. 3H), 4.59 (m, IH), 2.15 (m, IH), 1.99 (m, 2H), 1.68 (m, 3H), 1.53 (m, IH), 1.38 (m, 2H), 1.04 (d, 3H); MS (DCI/NH 3 ) m/z 257 [M+H] + .
  • Example 44 8-(3-ethoxy-l-ethylpropoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 37 substituting l-ethoxypentan-3-ol for heptan-3-ol. !
  • Example 48 8-(l,2-diethylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 37 substituting 4-ethylhexan-3-ol for heptan-3-ol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.94 (d, IH), 7.28 (t, IH), 7.18 (m, IH), 7.08 (m, 2H), 4.47 (m, IH), 2.01 (m, IH), 1.61-1.82 (m, 3H), 1.50 (m, 2H), 1.29 (m, IH), 0.98 (m, 6H), 0.86 ( , 3H); MS (DCI/NH 3 ) m/z 273 [M+H] + .
  • Example 50 8-(l,3-dimethylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 37 substituting 4-methylpentan-2-ol for heptan-3-ol.
  • H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.96 (d, IH), 7.3 (t, IH), 7.20 (m, IH), 7.13 (m, IH), 7.06 (d, IH), 4.67 (m, IH), 2.01 (m, IH), 1.83 (m, IH), 1.53 (m, IH), 1.41 (d, 3H), 0.96 (d, 3H), 0.92 (d, 3H); MS (DCI/NH 3 ) m/z 245 [M+H] + .
  • Example 53 8-(( 1 -isopropylpentyl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 37 substituting 2-methylheptan-3-ol for heptan-3-ol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.94 (d, IH), 7.29 (m, IH), 7.17 (m, IH), 7.08 (m, 2H), 4.28 (m, IH), 2.19 (m, IH), 1.98 (m, IH), 1.68 (m, IH), 1.46 (m, IH), 1.31 (m, 3H), 1.01 (m, 6H), 0.86 (m, 3H); MS (DCI/NH 3 ) m/z 273 [M+H] + .
  • Example 54 8-(l-benzylpropoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 37 substituting l-phenylbutan-2-ol for heptan-3-ol.
  • 2 H NMR 500 MHz, CDCI3 ⁇ ppm 7.86 (d, IH), 7.30 (m, 2H), 7.23 (m, 2H), 7.16 (m, 3H), 6.99 (m, IH), 6.88 (d, IH), 4.59 ( , IH), 3.27 (dd, IH), 2.99 (dd, IH), 1.73-1.97 (m, 2H), 1.02 (t, 3H); MS (DCI/NH 3 ) m/z 293
  • Example 55 8-( 1 -(4-fluorophenyl)ethoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 37 substituting l-(4-fluorophenyl)ethanol for heptan-3-ol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.92 (d, IH), 7.48 (m, 2H), 7.14 (m, 2H), 7.01 (m, 3H), 6.94 (m, IH), 5.50 (q, IH), 1.84 (d, 3H); MS (DCI/NH 3 ) m/z 283 [M+H] + .
  • Example 57 8-( 1 -methyl-2-phenylethoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 58 8-(((l S)-l -methylpropyl)oxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 37 substituting (R)-(-)-2-butanol for heptan-3-ol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.95 (d, IH), 7.30 (t, IH), 7.19 (m, IH), 7.11 (m, IH), 7.06 (d, IH), 4.51 (m, IH), 2.01 (m, IH), 1.76 (m, IH), 1.43 (d, 3H), 1.01 (t, 3H); MS (DCI/NH 3 ) m/z 217 [M+H] + .
  • Example 59 8-(2,3 -dihydro- 1 H-inden-2-yloxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 37 substituting 2-indanol for heptan-3-ol.
  • 1H NMR 500 MHz, DMSO-d 6 ) ⁇ ppm 8.37 (d, IH), 7.49 (m, 3H), 7.31 (m, 2H), 7.21 (m, 2H), 7.11 (d, IH), 5.51 (m, IH), 3.59 (d, IH), 3.55 (d, IH), 3.28 (d, IH), 3.24 (d, IH); MS (DCI NH 3 ) m/z 277 [M+H] + .
  • Example 61 8-(2-(l-naphthyl)ethoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 62 8-(( 1 -ethyl-4-methylpentyl)oxy)quinolin-2-amine
  • a 7.5 mL conical microwave vessel (Personal Chemistry) equipped with a septum cap and a magnetic stirring bar was charged with PS-PPh 3 resin (Aldrich Chemical Co., Inc, 140 mg, 4.40 equiv), 2-amino-8-hydroxyquinoline (15.0 mg, 0.0960 mmol) and DBAD (69 mg, 3.2 equiv) and purged by passing a stream of N 2 for 45 seconds.
  • Anhydr. THF 1.5 mL was added and contents of the vessel were stirred for 10 min.
  • Example 64 8-(((lR,5S)-3,3,5-trimethylcyclohexyl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 62 substituting cis-3,3,5-trimethylcyclohexanol for 6-methyl-3-heptanol.
  • Example 65 8-(benzyloxy)quinolin-2-amine A 20 mL scintillation vial with a septum cap was charged with PS-PPh 3 resin (Aldrich Chemical Co., Inc, 100 mg, 2.2 equiv), 2-amino-8-hydroxyquinoline (22 mg, 0.14 mmol) and DBAD (51 mg, 1.6 equiv) and purged by passing a stream of N2 for 45 seconds. Anhydr. THF (3 mL) was added and the contents of the vial were shaken for 5 min. Then, a solution of benzyl alcohol (1.25 equiv) in anhydr. THF (1 mL) was added and the resulting suspension was shaken at room temperature for 8 h.
  • PS-PPh 3 resin Aldrich Chemical Co., Inc, 100 mg, 2.2 equiv
  • 2-amino-8-hydroxyquinoline 22 mg, 0.14 mmol
  • DBAD 51 mg, 1.6 equiv
  • the suspension was filtered, and the resin washed with THF (2.5, 3.5 and 3.0 mL). The filtrate and washings were combined and evaporated in vacuo.
  • the resulting crude product was then dissolved in a mixture of DCM (1 mL), thf (1 mL) and MeOH (3 mL) and the solution was added to MP-TsOH resin (Argonaut Technologies, Inc., 0.5 g). The resulting suspension was agitated at room temperature for 1.5 h. The supernatant was subsequently drained and the resin was washed with DCM (2 mL), MeOH (2 mL), THF (2 mL) and DCM (2 mL).
  • the washed resin was treated with 2 N NH 3 in MeOH (4 mL) at room temperature for 1 h. The supernatant was collected and the resin was washed with MeOH (3 mL) and DCM (3 mL). The washes were combined with the collected supernatant. The NH 3 /MeOH treatment and washes were then repeated. The filtrate and the washes were combined with previously collected and evaporated in vacuo. The residue was dissolved in 1.5 mL of a 1 :1 mixture of DMSO/MeOH and purified by preparative reverse-phase HPLC.
  • Example 66 8-((3-(trifluoromethyl)benzyl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 65 substituting 3-(trifluoromethyl)benzyl alcohol for benzyl alcohol.
  • 1H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.88 (d, IH), 7.78 (s, IH), 7.72 (d, IH), 7.56 (d, IH), 7.48 (t, IH), 7.26 (m, IH), 7.12 (t, IH), 6.96 (m, IH), 6.78 (d, IH), 5.42 (s, 2H); MS (DCI NH 3 ) m/z 319 [M+H] + .
  • Example 69 8-(((3R)- 1 -benzylpyrrolidin-3 -yl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 65 substituting (S)-l-benzyl-3-pyrrolidinol for benzyl alcohol.
  • Example 71 8-((l,5-dimethylhex-4-enyl)oxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 72 8-((( 1 R)- 1 -phenylethyl)oxy)quinolin-2 -amine
  • the title compound was prepared according to the procedure described in Example 65 substituting (S)-(-)-l-phenylethanol for benzyl alcohol.
  • l B NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.83 (d, IH), 7.47 (m, 2H), 7.32 (m, 2H), 7.23 (m, IH), 7.13 (dd, IH), 7.01 (t, IH), 6.84 (dd, IH), 6.76 (m, IH), 5.51 (m, IH), 1.82 (d, 3H); MS (DCI NH3) m/z 265 [M+H] + .
  • Example 77 3 ((2-aminoquinolin-8-yl)oxy)propan- 1 -ol
  • the reaction was allowed to slowly warm to room temperature and stirring was maintained for 8 h. Then, 0.652 g (2 equiv) of PPh 3 was added, the reaction mixture was cooled to 0 °C and 0.431 g (1.5 equiv) of DBAD in 15 mL THF was added dropwise over 10 minutes. The reaction mixture was stirred at room temperature for 12 h. The solution was evaporated in vacuo, the residue was dissolved in DMA (25 mL) and MP-TsOH resin (Argonaut Technologies, Inc., 4.5 g) was added. The resulting suspension was agitated at room temperature for 12 h.
  • the supernatant was subsequently drained and the resin was washed with DMA (2x20 mL), MeOH (2x20 mL) and DMA (20 mL).
  • the washed resin was treated with a mixture of 2 N NH 3 in MeOH (15 mL) and DMA (5 mL) at room temperature for 1 h.
  • the solution was drained and the basic wash was repeated two more times. Filtered solutions were combined.
  • PS-PPh 3 resin Aldrich Chemical Co., Inc, 60 mg, 2.4 equiv
  • DBAD 28 mg, 1.6 equiv
  • the suspension was filtered, and the resin washed with THF (3x3.0 mL). The filtrate and washings were combined and evaporated in vacuo.
  • the residue was then treated with 6.0 mL of 4 M HCl in dioxane at room temperature for 6 h. The resulting solution was evaporated in vacuo.
  • the residue was dissolved in 1.5 mL of a 1 :1 mixture of DMSO/MeOH and purified by preparative reverse-phase HPLC.
  • Example 80 8-(3-((2-aminoquinolin-8-yl)oxy)propoxy)quinolin-2-ol
  • the title compound was prepared according to the procedure described in Example
  • Example 81 6-(3-((2-aminoquinolin-8-yl)oxy)propoxy)quinolin-2-ol
  • the title compound was prepared according to the procedure described in Example 78 substituting 2,6-quinolinediol for 8-hydroxyquinaldine.
  • Example 82 4-(3-((2-aminoquinolin-8-yl)oxy)propoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 78 substituting 2-aminoquinolin-4-ol for 8-hydroxyquinaldine.
  • Example 83 8-(3-phenoxypropoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 84 8-(3-(3,5-dichlorophenoxy)propoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 78 substituting 3,5-dichlorophenol for 8-hydroxyquinaldine.
  • 1HNMR 500 MHz, CDC1 3 ) ⁇ ppm 7.99 (d, IH), 7.32 (t, IH), 7.24 (m, IH), 7.14 (m, IH), 7.05 (d, IH), 6.86 (m, IH), 6.82 (m, 2H), 4.35 (m, 4H), 2.49 (m, 2H); MS (DCI/NH 3 ) m/z 363 [M+H] + .
  • Example 85A 8-( 1 -Methyl-but-3 -enyloxy)-quinolin-2-ylamine To a 100 mL round bottom flask equipped with a stirring bar, under N 2 , was added
  • Example 85B 4-((2-aminoquinolin-8-yl)oxy)pentan- 1 -ol To a 100 mL round bottom flask containing 1.33 g (5.83 mmol) of 8-(l-methyl-but-
  • Example 88 8-(4-(3,5-dichlorophenoxy)-l-methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 86 substituting 3,5-dichlorophenol for 8-hydroxyquinaldine.
  • Example 90 8-(l-methyl-4-(quinolin-7-yloxy)butoxy)quinolin-2-amme
  • the title compound was prepared according to the procedure described in Example 86 substituting 7-hydroxyquinoline for 8-hydroxyquinaldine.
  • HNMR 500 MHz, CDC1 3 ) ⁇ ppm 8.99 (br d, IH), 8.61 (d, IH), 7.88 (d, IH), 7.83 (d, IH), 7.77 (d, IH), 7.65 (dd, IH), 7.30 (m, 2H), 7.19 (m, IH), 7.14 (d, IH), 7.01 (d, IH), 4.73 (m, IH), 4.22-4.42 (m, 2H), 2.19 (m, 2H), 2.00 (m, 2H), 1.48 (d, 3H); MS (DCI NH 3 ) m z 373 [M+H] + .
  • Example 92 methyl 3 -((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)benzoate
  • PS-PPh 3 resin Aldrich Chemical Co., Inc, 120 mg, 4.4 equiv
  • a solution of methyl 3-hydroxybenzoate (0.41 mL, 0.30 mM) in anhydr.
  • THF DMA for phenols not soluble in THF
  • DBAD 0.50 mL; 60 mg/mL
  • Example 93 8-( 1 -methyl-4-(3 ,4,5-trimethylphenoxy)butoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting methyl 3,4,5-trimethylphenol for methyl 3-hydroxybenzoate. !
  • Example 94 methyl 0-(4-((2-aminoquinolin-8-yl)oxy)pentyl)-L-tyrosinate
  • the title compound was prepared according to the procedure described in Example 92 substituting methyl methyl L-tyrosinate for methyl 3-hydroxybenzoate.
  • Example 95 8-( 1 -methyl-4-(2-naphthyloxy)butoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting 2-naphthol for methyl 3-hydroxybenzoate. !
  • Example 96 l-(4-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)-3-methylphenyl)ethanone
  • the title compound was prepared according to the procedure described in Example 92 substituting l-(4-hydroxy-3-methylphenyl)ethanone for methyl 3-hydroxybenzoate.
  • Example 97 8-(l-methyl-4-(4-propylphenoxy)butoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 4-propylphenol for methyl 3-hydroxybenzoate.
  • H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.93 (d, IH), 7.29 (t, IH), 7.18 (m, IH), 7.13 (d, IH), 7.02 (m, 3H), 6.74 (m, 2H), 4.70 (m, IH), 4.00 (m, 2H), 2.49 (t, 2H), 2.20 (m, IH), 1.97 (m, 3H), 1.59 (m, 2H), 1.46 (d, 3H), 0.91 (t, 3H); MS (DCI/NH 3 ) m/z 365 [M+H] + .
  • Example 100 2-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)benzonitrile
  • the title compound was prepared according to the procedure described in Exampl 92 substituting 2-hydroxybenzonitrile for methyl 3-hydroxybenzoate.
  • Example 101 2-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)benzamide
  • the title compound was prepared according to the procedure described in Example 92 substituting salicylamide for methyl 3-hydroxybenzoate.
  • 1H NMR 500 MHz, DMSO- d 6 ) ⁇ ppm 7.76 (dd, IH), 7.35-7.58 (m, 6H), 7.10 (d, IH), 7.01 (m, IH), 4.87 (m, IH), 4.18 (m, 2H), 1.84-2.05 (m, 4H), 1.40 (d, 3H); MS (DCI/NH 3 ) m/z 366 [M+H] + .
  • Example 102 8-(l-methyl-4-(2-methyl-5-nitrophenoxy)butoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting 2-methyl-5-nitrophenol for methyl 3-hydroxybenzoate.
  • X H NMR 500 MHz, CDC1 3 ) ⁇ ppm 7.96 (d, IH), 7.68 (dd, IH), 7.59 (d, IH), 7.30 (t, IH), 7.21 (m, IH), 7.18 (m, IH), 7.13 (d, IH), 7.01 (d, IH), 4.71 (m, IH), 4.15 (m, IH), 4.08 (m, IH), 2.25 (m, IH), 2.21 (s, 3H), 2.12 (m, IH), 2.01 (m, 2H), 1.49 (d, 3H); MS (DCI7NH 3 ) m/z 382 [M+H] + .
  • Example 103 8-(4-((5-amino- 1 -naphthyl)oxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 5-amino-l-naphthol for methyl 3-hydroxybenzoate. !
  • Example 108 ethyl 2-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)-5-methylbenzoate The title compound was prepared according to the procedure described in Example
  • Example 109 8-(4-(4-bromo-2-fluorophenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 4-bromo-2-fluorophenol for methyl 3-hydroxybenzoate.
  • Example 110 N-(3-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)phenyl)urea
  • the title compound was prepared according to the procedure described in Example 92 substituting N-(3-hydroxyphenyI)urea for methyl 3-hydroxybenzoate.
  • Example 111 4-(4-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)phenyl)butan-2-one
  • the title compound was prepared according to the procedure described in Example 92 substituting 4-(4-hydroxyphenyl)butan-2-one for methyl 3-hydroxybenzoate.
  • Example 112 ethyl 2-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)benzoate
  • the title compound was prepared according to the procedure described in Example 92 substituting ethyl salicylate for methyl 3-hydroxybenzoate.
  • H NMR 500 MHz, CDCI3 ⁇ ppm 7.94 (d, IH), 7.71 (dd, IH), 7.40 (m, IH), 7.28 (t, IH), 7.16 (m, 2H), 7.00 (d, IH),
  • Example 113 methyl 2-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)-5-methoxybenzoate
  • the title compound was prepared according to the procedure described in Example 92 substituting methyl 2-hydroxy-5-methoxybenzoate for methyl 3-hydroxybenzoate.
  • Example 114 8-(4-(4-amino-2-chlorophenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 4-amino-2-chlorophenol for methyl 3-hydroxybenzoate. !
  • Example 118 8-(4-(l,r-biphenyl-3-yloxy)-l-methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting l,l'-biphenyl-3-ol for methyl 3-hydroxybenzoate.
  • Example 120 8-(4-(2-ethoxy-5-(( 1 E)-prop- 1 -enyl)phenoxy)- 1 -methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 121 methyl 2-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)-4-methoxybenzoate
  • the title compound was prepared according to the procedure described in Example 92 substituting methyl 2-hydroxy-4-methoxybenzoate for methyl 3-hydroxybenzoate.
  • Example 122 8-(4-(2-benzylphenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 2-benzylphenol for methyl 3-hydroxybenzoate.
  • Example 123 8-(4-(2-fluoro-4-nitrophenoxy)- 1 -methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting 2-fluoro-4-nitrophenol for methyl 3-hydroxybenzoate.
  • Example 128 8-(4-((2,2-dimethyl-2,3-dihydro-l-benzofuran-7-yl)oxy)-l-methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 2,2-dimethy 1-2,3 -dihydro- l-benzofuran-7-ol for methyl 3-hydroxybenzoate.
  • Example 129 8 (4-(2-isoxazol-5 -ylphenoxy)- 1 -methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 130 6-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)- 1 ,3 -benzoxathiol-2-one
  • the title compound was prepared according to the procedure described in Example 92substituting 6-hydroxy- 1 ,3 -benzoxathiol-2-one for methyl 3 -hydroxybenzoate .
  • Example 131 8-(4-(2-methoxy-4-propylphenoxy)-l-methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 4-allyl-2-methoxyphenol for methyl 3-hydroxybenzoate.
  • Example 132 8-(4-(2-chloro-3-(trifluoromethyl)phenoxy)-l-methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 2-chloro-3-(triflouromethyl)phenol for methyl 3-hydroxybenzoate.
  • Example 135 8-(l-methyl-4-(4-methylphenoxy)butoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting o-cresol for methyl 3-hydroxybenzoate.
  • l U NMR 500 MHz, DMSO-d 6 ) ⁇ ppm 8.36 (d, IH), 7.48 (m, 3H), 7.40 (m, 2H), 7.13 (d, IH), 7.02 (m, IH), 6.74 (m, IH), 4.83 (m, IH), 3.99 (m, 2H), 2.22 (m, 3H), 1.76-2.08 (m, 4H), 1.40 (d, 3H); MS (DCI/NH 3 ) m/z 337 [M+H] + .
  • Example 138 8-(4-(3 -mefhoxyphenoxy)- 1 -methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting 3-methoxyphenol for methyl 3-hydroxybenzoate. 1H NMR (500 MHz,
  • Example 139 8-(4-(4-methoxyphenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 4-methoxyphenol for methyl 3-hydroxybenzoate.
  • Example 140 8-(4-(2-fluorophenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 2-flourophenol for methyl 3-hydroxybenzoate.
  • Example 142 8-f 4-f 4-fluorophenoxy)- 1 -methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 143 8-(4-(2-chlorophenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 2-chlorophenol for methyl 3-hydroxybenzoate.
  • Example 144 8-(4-(3 -chlorophenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 3-chlorophenol for methyl 3-hydroxybenzoate.
  • Example 146 8-(4-(2-bromophenoxy)- 1 -methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 147 8-(4-(3 -bromophenoxy)- 1 -methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting 3-bromophenol for methyl 3-hydroxybenzoate. !
  • Example 148 8-(4-(4-bromophenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 4-bromophenol for methyl 3-hydroxybenzoate.
  • Example 149 3-((4-((2-aminoquinolin-8-yl)oxy)pentyl)oxy)benzonitrile
  • the title compound was prepared according to the procedure described in Example 92 substituting 3-cyanophenol for methyl 3-hydroxybenzoate.
  • Example 151 8-(l-methyl-4-(3-(trifluoromethyl)phenoxy)butoxy)quinolin-2 -amine The title compound was prepared according to the procedure described in Example
  • Example 152 8-(l-methyl-4-(4-(trifluoromethyl)phenoxy)butoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 4-(triflouromethyl)phenol for methyl 3-hydroxybenzoate.
  • J H NMR 500 MHz, DMSO-de) ⁇ ppm 8.36 (d, IH), 7.58 (m, 2H), 7.45 (m, 3H), 7.12 (d, IH), 7.02 (m, 2H), 4.76-4.96 (m, IH), 4.13 (m, 2H), 1.80-2.06 (m, 4H), 1.40 (d, 3H); MS (DCI/NH 3 ) m/z 391 [M+H] + .
  • Example 153 8-(l-methyl-4-(3-(trifluoromethoxy)phenoxy)butoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 3-(triflouromethoxy)phenol for methyl 3-hydroxybenzoate.
  • H NMR 500 MHz, DMSO-d 6 ) ⁇ ppm 8.36 (d, IH), 7.48 (m, 2H).
  • Example 154 8-(4-(2,3 -dimethylphenoxy)- 1 -methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting 2,3-dimethylphenol for methyl 3-hydroxybenzoate. ! H NMR (500 MHz,
  • Example 155 8-(4-(2,4-dimethylphenoxy)- 1 -methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting 2,4-dimethylphenol for methyl 3-hydroxybenzoate. !
  • Example 157 8-(4-(3 ,4-dimethylphenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 3,4-dimethylphenol for methyl 3-hydroxybenzoate.
  • Example 160 8-(4-(2,3-dichlorophenoxy)-l-methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 161 8-(4-(2,4-dichlorophenoxy)- 1 -methylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 92 substituting 2,4-dichlorophenol for methyl 3 -hydroxybenzoate.
  • H NMR 500 MHz, DMSO-d 6 ) ⁇ ppm 8.36 (m, IH), 7.31-7.58 (m, 5H), 6.95-7.24 (m, 2H), 4.74-5.11 (m, IH), 3.84-4.11 ( , 2H), 1.80-2.14 (m, 4H), 1.41 (m, 3H); MS (DCI/NH 3 ) m z 392 [M+H] + .
  • Example 162 8-(4-(2,5-dichlorophenoxy)-l-methylbutoxy)quinolin-2-amine .
  • the title compound was prepared according to the procedure described in Example 92 substituting 2,5-dichlorophenol for methyl 3-hydroxybenzoate.
  • 'H NMR 500 MHz, DMSO-de) ⁇ ppm 8.36 (m, IH), 7.42 (m, 4H), 7.16 (m, 2H), 6.95 (m, IH), 4.79-5.07 (m, IH), 4.16 (m, 2H), 1.73-2.10 (m, 4H), 1.41 (m, 3H); MS (DCI/NH 3 ) m/z 392 [M+H] + .
  • Example 164 8-(4-(3,4-dichlorophenoxy)-l-methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • reaction mixture was cooled in an ice bath and a solution of 4.76 g (0.75 equiv) of DBAD in 25 mL of anhydr. THF was added dropwise over 15 minutes. The reaction was allowed to slowly warm to room temperature, and stirring was maintained for an additional 6 h. The reaction mixture was then evaporated in vacuo and the resulting residue dissolved in 150 mL of EtOAc. The solution was washed with 2 N HCl (3 x 400 mL). The aqueous layers were combined and basified with 10 N
  • Example 166 N-propyl-8-(l,3,3-trimethylbutoxy)quinolin-2-amine To a 4 mL scintillation vial was added a stir bar and the title compound from Example 16 (15.0 mg, 0.058 mmol). To this was added 0.42 mL of a 1 :1
  • Example 167 ⁇ D 20 +107°.
  • 1H NMR 300 MHz, DMSO-d 6 ⁇ ppm 7.83 (m, IH), 7.16 (m, IH), 7.03 (m, 2H), 6.76 (m, IH), 6.18-6.38 (m, 2H), 4.72 (m, IH), 1.85 (m, IH), 1.47 (m, IH), 1.24 (m, 3H), 0.84-1.04 (m, 9H); MS (DCI/NH 3 ) m/z 259 [M+H .
  • Example 168 ⁇ ⁇ D 20 -111°.
  • 1H NMR 300 MHz, DMSO-d 6 ) ⁇ ppm 7.83 (m, IH), 7.16 (m, IH), 7.03 (m, 2H), 6.76 (m, IH), 6.18-6.38 (m, 2H), 4.72 (m, IH), 1.85 (m, IH), 1.47 (m, IH), 1.24 (m, 3H), 0.84-1.04 (m, 9H); MS (DCI/NH 3 ) m/z 259 [M+H] + .
  • Example 169 N-((5-(2-(trifluoromethyl)phenyl)-2-furyl)methyl)-8-(l,3,3-trimethylbutoxy)quinolin-2- amine
  • the title compound was prepared according to the procedure described in Example 166 substituting 5-(2-(trifluoromethyl)phenyl)-2-furaldehyde for propionaldehyde.
  • Example 170 N-((5-(2-nitrophenyl)-2-furyl)methyl)-8-( 1 ,3 ,3 -trimethylbutoxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 166 substituting 5-(2-nitrophenyl)-2-furaldehyde for propionaldehyde.
  • Example 172 8-hexylquinolin-2-amine A solution of 2-amino-8-trifluoromethanesulfonylquinoline (50.0 mg, 0.171 mmol) in THF (1.0 mL) was degassed by bubbling N through the solution under vacuum for 5 min. The solution was added to a glass screw-top tube containing Pd(dppf) Cl 2 -CH 2 Cl 2 (13.9 mg, 0.1 equiv). Argon was then bubbled through the mixture for 1 minute, and 1-hexylzinc bromide (1.0 mL, 1 M in THF) was added. The tube was quickly sealed and placed in a heater/shaker at 65 °C for 20 h. The reaction mixture was cooled to room temperature, filtered through a 0.45 ⁇ m filter, and concentrated. The residue was dissolved in 1 : 1
  • Example 173 8-( 1 -methylpentyl)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 172 substituting 1-methylpentylzinc bromide for 1-hexylzinc bromide.
  • J H NMR 300 MHz, DMSO-de) ⁇ 9.20 (br s, IH), 8.45 (br s, IH), 8.37 (d, IH), 7.77 (d, IH), 7.70 (d, IH), 7.49 (br s, IH), 7.12 (d, IH), 1.71-1.67 (m, 3H), 1.28-1.14 (m, 4H), 0.82 (d, 3H), 0.74 (t, 3H); MS (DCI/NH3) m/z 228 [M] + .
  • Example 174 8-( 1 -ethylbutyl)quinolin-2-amine The title compound was prepared according to the procedure described in Example 172 substituting 1-ethylbutylzinc bromide for 1-hexylzinc bromide.
  • Example 175 8-( 1 -ethylpentyl)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 172 substituting 1-ethylpentylzinc bromide for 1-hexylzinc bromide.
  • Example 178 8-(3-((2-aminoquinolin-8-yl)oxy)butoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 179 8-(3-(2-aminoquinolin-8-yloxy)propoxy)quinolin-2-amine
  • PS-PPI13 resin Aldrich Chemical Co., Inc, 200 mg, 4 equiv
  • 2-amino-8-hydroxyquinoline 100 mg, 5 equiv
  • Anhydr. THF (3.0 mL) was added and contents of the vial were agitated for 3 min.
  • 1,3-propanenediol (10 mg, 0.13 mmol) was added to the vial followed by DBAD (66 mg, 2 equiv) and the resulting suspension was agitated at room temperature for 15 min. Then additional DBAD (33 mg, 1 equiv) was added and the mixture was agitated for additional 15 min. The last addition of DBAD was repeated and the mixture was agitated for 6 h. The suspension was then filtered, and the resin washed with DMA (6 x 3.0 mL). The filtrate and washings were combined and evaporated in vacuo. The residue was dissolved in DMA (10 mL) and MP-TsOH resin (Argonaut Technologies, Inc., 4.5 g) was added.
  • the resulting suspension was agitated at room temperature for 12 h.
  • the supernatant was subsequently drained and the resin was washed with DMA (10 mL), MeOH (10 mL) and DMA 00 mL) and MeOH (10 mL).
  • the washed resin was treated with a mixture of 2 N NH 3 in MeOH (15 mL) and DMA (5 mL) at room temperature for 1 h.
  • the solution was drained and the basic wash was repeated two more times.
  • the filtered solutions were combined.
  • the resin was washed with MeOH (10 mL), DMA (10 mL), MeOH (10 mL), DMA (10 mL) and MeOH (10 mL).
  • the washes were combined with the previously collected solutions and evaporated in vacuo.
  • Example 180 8-((2E)-but-2-enyloxy)quinolin-2 -amine
  • 1.51 mL of 3-chloro-l-butene (15.0 mmol) was added in one portion, and the mixture was heated to 65 °C in an oil bath. After 48 h, the solvent was evaporated and the residue dissolved in EtOAc and washed with H 2 0. The combined aqueous layers were back-extracted with EtOAc.
  • Example 181 A 2,2-dimethyl-N-(8-(l,3,3-trimethylbutoxy)quinolin-2-yl)propanamide To a 20 mL scintillation vial was added a stir bar, the title compound from Example 16 (161 mg , 0.624 mmol) and 1.5 mL of THF. To the resultant solution was added Et 3 ⁇ (0.174 mL, 2 equiv) and trirnethylacetylchloride (93 ⁇ L, 1.2 equiv). The solution was allowed to stir overnight, after which time the mixture placed directly on a silica column and eluted with EtOAc/hexanes to afford the title compound.
  • Example 18 IB 2,2-dimethyl-N-(3-methyl-8-(l,3,3-trimethylbutoxy)qumolin-2-yl)propanamide
  • a 50 mL three-neck flask with a stir bar was charged with the title compound from Example 181 A (270 mg, 0.790 mmol) and 3 mL of THF.
  • the flask was cooled to 0 °C in an ice bath and 0.9 mL of a 2.5 M solution of n-BuLi in THF was added slowly via syringe.
  • the resultant solution was allowed to stir at 0 °C for 4 h, and then cooled to -78 °C.
  • Example 181C 3-methyl-8-(l,3,3-trimethylbutoxy)quinolin-2-amine
  • a 20 mL glass tube was charged with the title compound from Example 181B(57.0 mg, 0.160 mmol), 1.5 mL of MeOH and sodium methoxide (26.0 mg, 3 equiv.).
  • the tube was sealed and heated to 70 °C in an oil bath for 12 h.
  • the reaction mixture was then allowed to cool to room temperature and was then quenched with saturated aqueous NH 4 C1.
  • the mixture was diluted with Et 2 0 and partitioned, the aqueous layer was washed with Et 2 O.
  • the ethereal layers were combined, dried, and filtered.
  • Example 183 A 3-((8-(l ,3,3-trimethylbutoxy)quinolin-2-yl)amino)propan-l -ol
  • the resulting solution was irradiated in Personal Chemistry Smith Synthesizer (220 °C for 25 min; 300 W). After cooling to room temperature, the contents were directly loaded on a silica gel column and eluted with EtOAc/hexanes to afford the title compound.
  • Example 183B N-(3 -((2-aminoquinolin-8-yl)oxy)propyl)-8-( 1 ,3 ,3 -trimethylbutoxy)quinolin-2-amine
  • PS-PPI1 3 resin Aldrich Chemical Co., Inc, 46 mg, 2.2 equiv
  • DBAD DBAD
  • Example 184 8-(4-(2-chloro-4-methylphenoxy)-l-methylbutoxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example 92 substituting 2-chloro-4-methylphenol for methyl 3-hydroxybenzoate.
  • a 4 dram scintillation vial was charged with 135 mg (0.509 mmol) of Example 195, l,3-benzodioxole-5-carbaldehyde (92.0 mg, 0.613 mmol), and macroporous sodium cyanoborohydride resin (400 mg, 2.55 mmol/g, 2 equiv).
  • a solution of 1:1 MeOH/dichloroethane with 1% AcOH was added (3 mL) and the reaction vessel shaken for approximately 16 hours. After this time the resin was filtered off and the solvents evaporated. The residue was dissolved in 1 : 1 MeOH/DMSO and purified on a reverse-phase HPLC column to afford the title compound.
  • Example 189 8-(((3S)-l-(2-fluorobenzyl)pyrrolidin-3-yl oxy)quinolin-2-amine The title compound was prepared according to the procedure described in Example
  • Example 190 8-(((3S)- 1 -( 1 , 1 '-biphenyl-4-ylmethyl)pyrrolidin-3 -yl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 188 substituting 4-biphenylcarboxaldehyde for l,3-benzodioxole-5-carbaldehyde.
  • Example 191 8-(((3S)-l-((3 -methyl- 1 -benzothien-2-yl)methyl)pyrrolidin-3 -yl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 188 substituting 3-methylbenzo(B)thiophene-2-carboxaldehyde for l,3-benzodioxole-5- carbaldehyde.
  • Example 194 tgrt-butyl 8-((3S)-pyrrolidin-3-yloxy)quinolin-2-ylcarbamate
  • the title compound was prepared according to the procedure described in Example 92 substituting (3 S)-hydroxy-pyrrolidine-l -carboxylic acid-tert-butyl ester for methyl 3- hydroxybenzoate.
  • Example 195 8-((3S)-pyrrolidin-3-yloxy)quinolin-2-amine To a 4 dram vial containing Example 194 (300 mg, 0.608 mmol) was added 3 mL of a 4 M solution of HCl in dioxane. The mixture was allowed to sit for 60 min and then the solvent was evaporated to afford the HCl salt of the title compound. !
  • Example 197 8-(((3S)- 1 -(2,3-dihydro- 1 ,4-benzodioxin-6-ylmethyl)pyrrolidin-3-yl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 188 substituting l,4-benzodioxan-6-carboxaldehyde for l,3-benzodioxole-5-carbaldehyde.
  • Example 199 8-(((3S ⁇ -l-(3-(trifluoromethyl)benzyl)py ⁇ olidin-3-yl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 188 substituting 3-(triflouromethyl)benzaldehyde for l,3-benzodioxole-5-carbaldehyde.
  • Example 200 8-(((3S)-l-((2,2-difluoro-l,3-benzodioxol-5-yl)methyl)pyrrolidin-3-yl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 188 substituting 2,2-diflouro-l,3-benzodioxolo-5-carboxaldehyde for l,3-benzodioxole-5- carbaldehyde.
  • Example 202 N-(2,3-dihydro-l,4-benzodioxin-6-ylmethyl)-8-(((3S)-l-(2,3-dihydro-l,4-benzodioxin-6- ylmethyl)pyrrolidin-3-yl)oxy)quinolin-2-amine
  • the title compound was prepared according to the procedure described in Example 188 substituting l,4-benzodioxan-6-carboxaldehyde for l,3-benzodioxole-5-carbaldehyde.
  • a 250 mL round bottom flask equipped with a magnetic stirring bar and a pressure equalizing dropping funnel was charged with 5.20 g (29.5 mmol) of 4-hydroxy-6-methyl- chromen-2-one.
  • the flask was purged with nitrogen and a solution of NEt 3 (8.3 mL) in DCM (60 mL) was added.
  • the resulting solution was cooled to -10 °C and trifluoromethanesulfonic anhydride (10.0 g; 1.2 eq) was added dropwise to the flask over 5 min.
  • the resulting mixture was kept at -10 °C for 2 h then diluted with 130 mL of 1:1 mixture of ether/hexanes.
  • Example 203 B 4-((3-hydroxypropyl)amino)-6-methyl-2H-chromen-2-one
  • a 7.5 L conical microwave reaction vessel (Personal Chemistry) was charged with the title compound from Example 203 A (0.030 g, 0.097 mol) and purged with N 2 . Then a solution of 3-amino-propan-l-ol (0.075 mL, 10 eq.) in a mixture of acetonitrile (2 mL) and triethylamine (0.2 mL) was added. The resulting solution was irradiated in Personal Chemistry Smith Synthesizer (150 °C for 180 s; 300 W). The reaction mixture was then evaporated in vacuo.
  • Example 204 A Trifluoromethanesulfonic acid 6-chloro-2-oxo-2H-chromen-yl ester
  • the title compound was prepared according to the procedure described in Example 203 A substituting 4-hydroxy-6-methyl-chromen-2-one for 4-hydroxy-6-chloro-chromen-2- one.
  • 1H NMR 300 MHz, MeOD-d 4 ) ⁇ 6.56 (s, IH), 7.26 (s, IH), 7.38 (d, IH, d), 7.64 (d, IH); MS (DCI/NH 3 ) m/z 329 [M+H] + .
  • Example 204 C 4-r3-(2-amino-quinolin-8-yloxy)-propylamino1-6-chIoro-chromen-2-one The title compound was prepared according to the procedure described in Example

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I), ou un sel, ou un promédicament thérapeutiquement approprié de ceux-ci, permettant d'antagoniser les effets de l'hormone de concentration de mélanine (MCH), par le biais du récepteur de l'hormone de concentration de mélanine, lesquels composés étant utiles pour la prévention ou le traitement de troubles alimentaires, de gain de poids et d'obésité.
PCT/US2003/018959 2002-06-18 2003-06-17 2-aminoquinolines servant d'antagonistes de recepteur de l'hormone de concentration de melanine WO2003105850A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17410902A 2002-06-18 2002-06-18
US10/174,109 2002-06-18
US10/460,139 2003-06-12
US10/460,139 US6989392B2 (en) 2002-06-18 2003-06-12 2-Aminoquinolines as melanin concentrating hormone receptor antagonists

Publications (1)

Publication Number Publication Date
WO2003105850A1 true WO2003105850A1 (fr) 2003-12-24

Family

ID=29738989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018959 WO2003105850A1 (fr) 2002-06-18 2003-06-17 2-aminoquinolines servant d'antagonistes de recepteur de l'hormone de concentration de melanine

Country Status (1)

Country Link
WO (1) WO2003105850A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011336A1 (fr) * 2007-07-18 2009-01-22 Taisho Pharmaceutical Co., Ltd. Composés de type quinoléine
US7803816B2 (en) 2005-09-30 2010-09-28 Hoffmann-La Roche Inc. MCH receptor antagonists
US7884114B2 (en) 2007-08-15 2011-02-08 Glaxo Group Limited Compounds
EP2289891A3 (fr) * 2005-08-04 2011-04-27 Palumed S.A. Nouveaux dérivés de polyquinoléines et leur utilisation thérapeutique.
WO2018031434A1 (fr) * 2016-08-08 2018-02-15 Merck Patent Gmbh Antagonistes de tlr7/8 et leurs utilisations
WO2021105497A1 (fr) * 2019-11-29 2021-06-03 University Of Copenhagen Inhibiteurs de nadph oxydase 2 à petite molécule
US11629134B2 (en) 2015-12-17 2023-04-18 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
CN116332918A (zh) * 2023-03-17 2023-06-27 遵义医科大学珠海校区 香豆素-喹啉衍生物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076984A2 (fr) * 1999-05-21 2000-12-21 Biovitrum Ab Nouveaux composes, et utilisation et preparation de ces derniers
WO2001040217A1 (fr) * 1999-11-30 2001-06-07 Pfizer Products Inc. Nouveaux derives benzoimidazole convenant comme agents antiproliferatifs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076984A2 (fr) * 1999-05-21 2000-12-21 Biovitrum Ab Nouveaux composes, et utilisation et preparation de ces derniers
WO2001040217A1 (fr) * 1999-11-30 2001-06-07 Pfizer Products Inc. Nouveaux derives benzoimidazole convenant comme agents antiproliferatifs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GLENNON, RICHARD A. ET AL: "5-HT1 and 5-HT2: binding characteristics of some quipazine analogs", JOURNAL OF MEDICINAL CHEMISTRY (1986), 29(11), 2375-80, XP002093299 *
SAMPEI, NOBUYOSHI ET AL: "2-Aminoquinoline derivatives", SANKYO KENKYUSHO NEMPO (1964), 16, 42-8, XP001155335 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289891A3 (fr) * 2005-08-04 2011-04-27 Palumed S.A. Nouveaux dérivés de polyquinoléines et leur utilisation thérapeutique.
US7803816B2 (en) 2005-09-30 2010-09-28 Hoffmann-La Roche Inc. MCH receptor antagonists
WO2009011336A1 (fr) * 2007-07-18 2009-01-22 Taisho Pharmaceutical Co., Ltd. Composés de type quinoléine
US7884114B2 (en) 2007-08-15 2011-02-08 Glaxo Group Limited Compounds
US11629134B2 (en) 2015-12-17 2023-04-18 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
US11512069B2 (en) 2016-08-08 2022-11-29 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
AU2017311047B2 (en) * 2016-08-08 2021-07-22 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
RU2758686C2 (ru) * 2016-08-08 2021-11-01 Мерк Патент Гмбх Антагонисты tlr7/8 и их применение
US10947214B2 (en) 2016-08-08 2021-03-16 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
WO2018031434A1 (fr) * 2016-08-08 2018-02-15 Merck Patent Gmbh Antagonistes de tlr7/8 et leurs utilisations
EP4198031A1 (fr) * 2016-08-08 2023-06-21 Merck Patent GmbH Antagonistes de tlr7/8 et leurs utilisations
WO2021105497A1 (fr) * 2019-11-29 2021-06-03 University Of Copenhagen Inhibiteurs de nadph oxydase 2 à petite molécule
CN116332918A (zh) * 2023-03-17 2023-06-27 遵义医科大学珠海校区 香豆素-喹啉衍生物及其制备方法与应用

Similar Documents

Publication Publication Date Title
US6989392B2 (en) 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
ES2392200T3 (es) Ésteres de diarilo como antagonistas del receptor opiáceo
US7074805B2 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
JP5617919B2 (ja) テトラヒドロベンゾチオフェン化合物
CA2950952C (fr) Modulateurs allosteriques negatifs (nam) du recepteur metabotropique du glutamate et utilisations de ceux-ci
US20060247439A1 (en) Mchir antagonists
JP4177435B2 (ja) 治療薬
CZ361392A3 (en) Novel azaheterocyclylmethyl-chromans
MX2007011366A (es) Derivados de 1-bencilindole-2-carboxamida.
JP2007523139A (ja) 治療薬
WO2008059866A1 (fr) Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur à substitution phénylamino et un groupe phényle dans lequel est introduit un ester en tant que substituants
WO2005085212A1 (fr) Derivé de la pyrimidine substitué
CA2806821C (fr) Compose de pyridine a cycle condense
BR112020012221A2 (pt) pirrolidina amidas substituídas ii
CA3201443A1 (fr) Derive de tetrahydroquinoline et son utilisation medicale
WO2003105850A1 (fr) 2-aminoquinolines servant d'antagonistes de recepteur de l'hormone de concentration de melanine
EP2261206A1 (fr) Composé d'indolinone
US20070185079A1 (en) Therapeutic agents I
US20050209274A1 (en) Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
AU644296B2 (en) 2-(1-piperidyl)ethanol derivatives, their preparation and their therapeutic application
CA2081256A1 (fr) Produits de reaction de methylchromanes avec la triazaspirodecanone
KR20210066848A (ko) 이속사졸 카르복사미드 화합물 및 이의 용도
CA2317515A1 (fr) Derives d'oxazol utilises comme agonistes du recepteur 1a de la serotonine
RU2127732C1 (ru) Эфиры бис-фенилпиперазинникотиновой кислоты, способ их получения (варианты), фармацевтическая композиция и способ лечения расстройств центральной нервной системы
JP2008544982A (ja) アルファ７ニコチン性受容体調節剤としてのチオフェン−２−カルボキサミド誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP